This database contains 21 studies, archived under the term: "Finland"
Click here to filter this large number of results.
Midlife cardiovascular risk factors and late cognitive impairment
Virta, Jyri J.,
Heikkilä, Kauko,
Perola, Markus,
Koskenvuo, Markku,
Räihä, Ismo,
Rinne, Juha O.,
Kaprio, Jaakko
Cardiovascular risk factors increase the risk of dementia in later life. The aims of the current study were to assess the effect of multiple midlife cardiovascular risk factors on the risk of cognitive impairment in later life, and to assess the validity of the previously suggested CAIDE Study risk score predicting dementia risk 20 years later. […]
Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients
Tikka, S.,
Mykkanen, K.,
Ruchoux, M.-M.,
Bergholm, R.,
Junna, M.,
Poyhonen, M.,
Yki-Jarvinen, H.,
Joutel, A.,
Viitanen, M.,
Baumann, M.,
Kalimo, H.
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common hereditary subcortical vascular dementia. It is caused by mutations in NOTCH3 gene, which encodes a large transmembrane receptor Notch3. The key pathological finding is the accumulation of granular osmiophilic material (GOM), which contains extracellular domains of Notch3, on degenerating vascular smooth […]
Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study
Taipale, Heidi,
Tanskanen, Antti,
Koponen, Marjaana,
Tolppanen, Anna-Maija,
Tiihonen, Jari,
Hartikainen, Sirpa
The objective of this study was to investigate the prevalence of acetylcholinesterase inhibitor (AChEI) and memantine use, duration of treatment, concomitant use of these drugs, and factors associated with the discontinuation of AChEI therapy during 2006-2009. We utilized data from a nationwide sample of community-dwelling individuals with a clinically verified Alzheimer’s disease diagnosed during the […]
Prospective flutemetamol positron emission tomography and histopathology in normal pressure hydrocephalus
Rinne, Juha O.,
Frantzen, Janek,
Leinonen, Ville,
Lonnrot, Kimmo,
Laakso, Aki,
Virtanen, Kirsi A.,
Solin, Olof,
Kotkansalo, Anna,
Koivisto, Anne,
Sajanti, Juha,
Karppinen, Atte,
Lehto, Hanna,
Rummukainen, Jaana,
Buckley, Chris,
Smith, Adrian,
Jones, Paul A.,
Sherwin, Paul,
Farrar, Gill,
McLain, Richard,
Kailajarvi, Marita,
Grachev, Igor D.
Unlabelled: BACKGOUND/OBJECTIVE: To determine the level of association between uptake of the amyloid positron emission tomography (PET) imaging agent [(18)F]flutemetamol and the level of amyloid-β measured by immunohistochemical and histochemical staining in a frontal cortical region biopsy site.; Methods: Seventeen patients with probable normal pressure hydrocephalus (NPH) underwent prospective [(18)F]flutemetamol PET and subsequent frontal cortical […]
Effects of the Finnish Alzheimer disease exercise trial (FINALEX): a randomized controlled trial
Pitkälä, Kaisu H.,
Pöysti, Minna M.,
Laakkonen, Marja-Liisa,
Tilvis, Reijo S.,
Savikko, Niina,
Kautiainen, Hannu,
Strandberg, Timo E.
Importance: Few rigorous clinical trials have investigated the effectiveness of exercise on the physical functioning of patients with Alzheimer disease (AD).; Objectives: To investigate the effects of intense and long-term exercise on the physical functioning and mobility of home-dwelling patients with AD and to explore its effects on the use and costs of health and […]
Effect of cholinergic stimulation in early Alzheimer’s disease – functional imaging during a recognition memory task
Miettinen, Pekka S.,
Pihlajamäki, Maija,
Jauhiainen, Anne M.,
Tarkka, Ina M.,
Gröhn, Heidi,
Niskanen, Eini,
Hänninen, Tuomo,
Vanninen, Ritva,
Soininen, Hilkka
Treatment of Alzheimer’s disease (AD) with acetylcholinesterase inhibitors (AChEI) enhances cholinergic activity and alleviates clinical symptoms. In the present functional magnetic resonance imaging (fMRI) study, we investigated the effect of the AChEI rivastigmine on cognitive function and brain activation patterns during a face recognition memory task. Twenty patients with newly-diagnosed mild AD were administered a […]
A phase II trial of tideglusib in Alzheimer’s disease
Lovestone, Simon,
Boadab, Mercè,
Dubois, Bruno,
Hüll, Michael,
Rinne, Juha O.,
Huppertz, Hans-Jürgen,
Calero, Miguel,
Andrés, María V.,
Gómez-Carrillo, Belén,
Leon, Teresa,
del Seri, Teodoro
Background: The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer’s disease (AD). Objective: To prove the clinical efficacy of an inhibitor of glycogen synthase kinase-3 (GSK-3), in AD. Methods: Mild to moderate (Mini-Mental State Examination (MMSE) score, 14–26) AD patients on cholinesterase inhibitor and/or memantine treatment […]
Predicting AD conversion: comparison between prodromal AD guidelines and computer assisted PredictAD tool
Liu, Yawu,
Mattila, Jussi,
Ruiz, Miguel Ángel Muñoz,
Paajanen, Teemu,
Koikkalainen, Juha,
van Gils, Mark,
Herukka, Sanna-Kaisa,
Waldemar, Gunhild,
Lötjönen, Jyrki,
Soininen, Hilkka
Purpose: To compare the accuracies of predicting AD conversion by using a decision support system (PredictAD tool) and current research criteria of prodromal AD as identified by combinations of episodic memory impairment of hippocampal type and visual assessment of medial temporal lobe atrophy (MTA) on MRI and CSF biomarkers.; Methods: Altogether 391 MCI cases (158 […]
Long-term statin therapy is associated with better episodic memory in aged familial hypercholesterolemia patients in comparison with population controls
Hyttinen, Laura,
TuulioHenriksson, Annamari,
Vuorio, Alpo F.,
Kuosmanen, Noora,
Härkänen, Tommi,
Koskinen, Seppo,
Strandberg, Timo E.
The cognitive status of aged familial hypercholesterolemia (FH) patients treated with long-term statin therapy was compared with that of population controls. A comprehensive cohort of 43 elderly (age > or = 65 years) patients all with the same FH North Karelia mutation living in North Karelia (eastern Finland) was identified, 37 of whom (aged 65 […]